We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed the most recent trading day at $6.97, moving +1.9% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a gain of 0.2%, and the technology-centric Nasdaq increased by 0.27%.
The vaccine maker's shares have seen a decrease of 1.44% over the last month, not keeping up with the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97%.
The upcoming earnings release of Novavax will be of great interest to investors. The company's upcoming EPS is projected at -$0.12, signifying a 112.12% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $130.5 million, indicating a 68.59% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.65 per share and a revenue of $1.07 billion, indicating changes of +315.45% and +56.76%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. At present, Novavax boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Novavax has a Forward P/E ratio of 2.58 right now. This represents a discount compared to its industry average Forward P/E of 18.51.
Also, we should mention that NVAX has a PEG ratio of 0.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.54 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Rises Higher Than Market: Key Facts
Novavax (NVAX - Free Report) closed the most recent trading day at $6.97, moving +1.9% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.14%. On the other hand, the Dow registered a gain of 0.2%, and the technology-centric Nasdaq increased by 0.27%.
The vaccine maker's shares have seen a decrease of 1.44% over the last month, not keeping up with the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97%.
The upcoming earnings release of Novavax will be of great interest to investors. The company's upcoming EPS is projected at -$0.12, signifying a 112.12% drop compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $130.5 million, indicating a 68.59% decline compared to the corresponding quarter of the prior year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $2.65 per share and a revenue of $1.07 billion, indicating changes of +315.45% and +56.76%, respectively, from the former year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. At present, Novavax boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Novavax has a Forward P/E ratio of 2.58 right now. This represents a discount compared to its industry average Forward P/E of 18.51.
Also, we should mention that NVAX has a PEG ratio of 0.06. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.54 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 74, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.